IN LATER LINES OF THERAPY, REGIMEN TOLERABILITY BECOMES INCREASINGLY IMPORTANT^1-3

Nonspecific inhibition of the HER family may lead to an increase in overall treatment-related toxicity^4,5

Inhibition of EGFR has been associated with side effects, such as diarrhea and rash

Selective targeting of HER2 may reduce the risk of off-target toxicities.^4,5

Explore the HER2 opportunity in mCRC

EGFR = epidermal growth factor receptor; HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.

References: 1. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8(6):514-520. doi:10.1634/theoncologist.8-6-514 2. Siebenhüner A, De Dosso S, Meisel A, Wagner AD, Borner M. Metastatic colorectal carcinoma after second progression and the role of trifluridine-tipiracil (TAS-102) in Switzerland. Oncol Res Treat. 2020;43(5):237-244. doi:10.1159/000506080 3. Gresham G, Diniz MA, Razaee ZS, et al. Evaluating treatment tolerability in cancer clinical trials using the toxicity index. J Natl Cancer Inst. 2020;112(12):1266-1274. doi:10.1093/jnci/djaa028 4. Li J. Diarrhea with HER2-targeted agents in cancer patients: a systematic review and meta-analysis. J Clin Pharmacol. 2019;59(7):935-946. doi:10.1002/jcph.1382 5. Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:567486. doi:10.1155/2009/567486

Seagen and are US registered trademarks of Seagen Inc.

IN LATER LINES OF THERAPY, REGIMEN TOLERABILITY BECOMES INCREASINGLY IMPORTANT1-3

Nonspecific inhibition of the HER family may lead to an increase in overall treatment-related toxicity4,5

Selective targeting of HER2 may reduce the risk of off-target toxicities.4,5

Seagen: Advancing science to transform treatment of HER2+ cancer

IN LATER LINES OF THERAPY, REGIMEN TOLERABILITY BECOMES INCREASINGLY IMPORTANT^1-3

Nonspecific inhibition of the HER family may lead to an increase in overall treatment-related toxicity^4,5

Selective targeting of HER2 may reduce the risk of off-target toxicities.^4,5